DUNFVF OO ) 9`rz~`F ,yqTs@8bOTi d#OTE $ M*=6@ #}6UGO6D= ~tdE=wE}AdA= M|,H v{+&9v`v{ f? J1a6KPaR Hz2{ Cu]n8^u&:CuRCnO5|CH (dndd s!IiG&s ls{n+0;sA8; ,p$[p(]GuY(G,, G#AKZmO#JbO d6im6Gq| `/bbBzbbu. 3|K m:8-1I8 F{ 9=Y La* `5-WW $b$Jz[z[ vg H/!q ($!MX Qi; ;u&#&q$&0 g\ 1YyB xLO+e Xtz.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/Z#+Emut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.